Teva Pharmaceutical Industries (NYSE:TEVA), a global leader in generic and specialty medicines with a market capitalization of $24.93 billion, has been navigating a complex market landscape with a mix ...

Allos AI today announced $5 million in seed financing led by Oxford Science Enterprises (OSE) to commercialize the industry's ...

Viatris remains a value play with low valuation and high free cash flow, but growth is hampered by legacy drug price erosion and lack of innovation. The company’s shift from small-molecule generics to ...

India's pharma industry shifts to value-driven approaches, focusing on complex generics, innovation, and expanding medical device exports.

Generic drugmakers continue to navigate a challenging U.S. market defined by persistent price erosion, intense competition and structurally thin margins. While demand for generics remains steady, ...

The Indian pharmaceutical industry is the world’s third-largest by volume, meeting approximately 20% of global generics demand ...

Economic Survey 2025-26: India's pharma industry shifts to value-driven approach, focusing on generics, biosimilars, and ...